BC Cancer Agency Researchers Develop Improved Prognostic Test for Follicular Lymphoma

Understanding risks and managing expectations around relapse

Y-ibritumomab tiuxetan and high-dose BEAM chemotherapy conditioning followed by autologous stem cell transplantation shows encouraging response and survival rates in refractory diffuse large B-cell lymphoma patients

Potential Role of Lymphocyte Development Gene Variants in Non-Hodgkin Lymphoma Risk

Rituximab helps overcome adverse effects of diabetes mellitus for patients with diffuse large B-cell lymphoma.